Scholarlink

<p>Uveal melanoma (UM) is the most common primary intraocular cancer, characterized by genetic variations associated with metastasis-related mortality. Current prognostic classifications primarily rely on large-scale copy number alterations without incorporating more precise genomic aberrations. We present a comprehensive analysis of whole-genome sequences from 40 primary UMs and matched normal tissues, revealing a complete landscape of somatic aberrations, including loss of heterozygosity and structural variations. It enabled the identification of two novel metastatic markers: <i>BAP1</i> aberrations (including loss of heterozygosity and structural variation-associated truncations, which were not revealed by previous targeted approaches) and 1q gains, thereby enhancing current molecular stratification for metastatic risk. Mutation timing analysis revealed that prevalent copy gains were often acquired early in life, several decades before tumour diagnosis. Notably, early 6p gain was frequently exclusive of <i>BAP1</i> aberrations and associated with a favourable prognosis, suggesting that metastatic potential in UM may be established early during tumorigenesis. Collectively, our findings provide molecular changes contributing to tumorigenesis and metastatic progression in UM and offer potential biomarkers for early detection and prognosis prediction.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Metastasis-related genomic aberrations and evolutionary trajectory in uveal melanoma

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年6月17日

查看全文
  • Chang Hyun Nam,
  • Yong Joon Kim,
  • Jeonghwan Youk,
  • Hyo Song Park,
  • Young Seok Ju,
  • Christopher Seungkyu Lee

摘要

Uveal melanoma (UM) is the most common primary intraocular cancer, characterized by genetic variations associated with metastasis-related mortality. Current prognostic classifications primarily rely on large-scale copy number alterations without incorporating more precise genomic aberrations. We present a comprehensive analysis of whole-genome sequences from 40 primary UMs and matched normal tissues, revealing a complete landscape of somatic aberrations, including loss of heterozygosity and structural variations. It enabled the identification of two novel metastatic markers: BAP1 aberrations (including loss of heterozygosity and structural variation-associated truncations, which were not revealed by previous targeted approaches) and 1q gains, thereby enhancing current molecular stratification for metastatic risk. Mutation timing analysis revealed that prevalent copy gains were often acquired early in life, several decades before tumour diagnosis. Notably, early 6p gain was frequently exclusive of BAP1 aberrations and associated with a favourable prognosis, suggesting that metastatic potential in UM may be established early during tumorigenesis. Collectively, our findings provide molecular changes contributing to tumorigenesis and metastatic progression in UM and offer potential biomarkers for early detection and prognosis prediction.